Tower Research Capital LLC (Trc) Annovis Bio, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.07 Billion
- Q1 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,798 shares of ANVS stock, worth $26,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,798
Previous 422
1036.97%
Holding current value
$26,676
Previous $7,000
714.29%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA358KShares$1.99 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$1.39 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$542,8170.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$403,6670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$393,5970.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $45.4M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...